Suppr超能文献

大承气汤通过调节肠道微生物群减轻轻度急性胰腺炎患者的炎症反应并促进胃肠功能恢复

[Dachengqi decoction reduces inflammatory response and promotes recovery of gastrointestinal function in patients with mild acute pancreatitis by regulating the intestinal microbiota].

作者信息

Li Junqiu, Dai Yancheng, Cao Hongyan, Xiao Tiegang, Ge Bingjing, Xing Lianjun, Yu Xiao, Fu Zhiquan

机构信息

Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China.

Second Department of Gastroenterology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. Corresponding author: Fu Zhiquan, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Feb;35(2):170-176. doi: 10.3760/cma.j.cn121430-20220921-00852.

Abstract

OBJECTIVE

To explore the therapeutic effect and mechanism of Dachengqi decoction on patients with mild acute pancreatitis (MAP).

METHODS

A parallel randomized controlled trial was conducted. Sixty-eight patients with acute pancreatitis (AP) admitted to Shanghai Traditional Chinese Medicine (TCM)-Integrated Hospital from March 2018 to February 2021 were enrolled. Referring to the condition on admission of the patients and whether they agreed to receive the Dachengqi decoction or not, they were divided into conventional treatment group and Dachengqi decoction group according to the principle of 1:1 equal randomness. Meanwhile, 20 healthy volunteers were recruited as controls. Both groups of patients were treated with octreotide, fasting, gastrointestinal decompression, antipyretic and analgesic, anti-inflammatory, inhibition of gastric acid and pancreatic juice secretion, maintenance of electrolyte balance and other western conventional medicine. The patients in the Dachengqi decoction group received Dachengqi decoction orally on the basis of routine treatment, 100 mL each time, twice a day, for seven consecutive days. The inflammation parameters [white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6)] before and after treatment and the recovery time of gastrointestinal function (first exhaust time, time to recover bowel sounds, first defecation time) of patients were recorded. 16S rRNA gene sequencing of stool samples was recorded, and normalized data were obtained after quality control and other related processing. The data were subjected to diversity analysis (Alpha diversity and Beta diversity) and linear discriminant analysis effect size analysis (LEfSe analysis) to observe changes in the gut microbiota of MAP patients. Spearman rank correlation coefficient was used to analyze the correlation between inflammatory indexes and microorganisms at the intestinal genus level. Blood, urine, stool samples, renal function, and electrocardiogram (ECG) during treatment of MAP patients were detected to assess the safety of the treatment.

RESULTS

Of the 68 patients with AP, 16 were excluded from moderate-severe AP, 4 were not collected or voluntarily abandoned treatment. Finally, 48 patients with MAP were enrolled, 24 in the conventional treatment group and 24 in the Dachengqi decoction group. The inflammation parameters levels at 7 days of treatment in both groups were significantly lower than those before treatment. CRP, PCT and IL-6 levels in the Dachengqi decoction group were significantly lower than those in the conventional treatment group [CRP (mg/L): 8.50 (3.50, 13.00) vs. 16.00 (9.25, 29.75), PCT (μg/L): 0.06 (0.03, 0.08) vs. 0.09 (0.05, 0.11), IL-6 (ng/L): 6.36 (3.96, 10.79) vs. 13.24 (6.69, 18.87), all P < 0.05]. The first exhaust time, time to recover bowel sounds and first defecation time in the Dachengqi decoction group were significantly shorter than those in the conventional treatment group [first exhaust time (days): 1.62±0.65 vs. 2.80±0.65, time to recover bowel sounds (days): 1.13±0.58 vs. 2.31±0.76, first defecation time (days): 3.12±0.75 vs. 4.39±0.76, all P < 0.05]. The analysis of intestinal microflora diversity showed that both the diversity and abundance of microbial communities were the highest in the healthy control group and the lowest in the conventional treatment group. In addition, the coincidence degree of microbial communities in healthy controls and MAP patients was small, while the coincidence degree of MAP patients among different treatment methods was relatively large. LEfSe analysis showed that Dachengqi decoction reduced the relative abundance of Escherichia coli-Shigella and Clostridium erysipelae, and increased the relative abundance of three beneficial bacteria, namely Lactobacillus, Rombutzia and Brutella. In the intestines of MAP patients, Lactobacillus mucilaginus and Lactobacillus conjunctus were significantly enriched. Correlation analysis showed that positive correlations between Escherichia coli-Shigella and the four inflammatory indicators including WBC, CRP, PCT, IL-6 were statistically significant (r value was 0.31, 0.41, 0.57, 0.43, respectively, all P < 0.05). There was no significant correlation between other bacteria and inflammatory indicators. During the treatment, there was no obvious abnormality in blood, urine and feces, renal function and ECG of MAP patients.

CONCLUSIONS

Dachengqi decoction could reduce inflammatory responses and promote recovery of intestinal microecological balance and gastrointestinal function in patients with MAP by regulating the composition of intestinal flora. No significant adverse effects were observed during the treatment period.

摘要

目的

探讨大承气汤对轻症急性胰腺炎(MAP)患者的治疗效果及作用机制。

方法

采用平行随机对照试验。选取2018年3月至2021年2月在上海中西医结合医院住院的68例急性胰腺炎(AP)患者。根据患者入院时的病情及是否同意接受大承气汤治疗,按照1:1等随机原则分为常规治疗组和大承气汤组。同时,招募20名健康志愿者作为对照组。两组患者均采用奥曲肽、禁食、胃肠减压、解热镇痛、抗炎、抑制胃酸和胰液分泌、维持电解质平衡等西医常规治疗。大承气汤组患者在常规治疗基础上口服大承气汤,每次100 mL,每日2次,连续服用7天。记录患者治疗前后的炎症指标[白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素-6(IL-6)]及胃肠功能恢复时间(首次排气时间、肠鸣音恢复时间、首次排便时间)。记录粪便样本的16S rRNA基因测序结果,经质量控制等相关处理后获得标准化数据。对数据进行多样性分析(α多样性和β多样性)及线性判别分析效应大小分析(LEfSe分析),以观察MAP患者肠道微生物群的变化。采用Spearman等级相关系数分析肠道属水平上炎症指标与微生物之间的相关性。检测MAP患者治疗期间的血液、尿液、粪便样本、肾功能及心电图(ECG),以评估治疗的安全性。

结果

68例AP患者中,排除16例中度 - 重度AP患者,4例未收集或自愿放弃治疗。最终纳入48例MAP患者,常规治疗组24例,大承气汤组24例。两组治疗7天时炎症指标水平均显著低于治疗前。大承气汤组CRP、PCT及IL-6水平显著低于常规治疗组[CRP(mg/L):8.50(3.50,13.00) vs. 16.00(9.25,29.75),PCT(μg/L):0.06(0.03,0.08) vs. 0.09(0.05,0.11),IL-6(ng/L):6.36(3.96,10.79) vs. 13.24(6.69,18.87),均P < 0.05]。大承气汤组首次排气时间、肠鸣音恢复时间及首次排便时间均显著短于常规治疗组[首次排气时间(天):1.62±0.65 vs. 2.80±0.65,肠鸣音恢复时间(天):1.13±0.58 vs. 2.31±0.76,首次排便时间(天):3.12±0.75 vs. 4.39±0.76,均P < 0.05]。肠道微生物群多样性分析显示,健康对照组微生物群落的多样性和丰度最高,常规治疗组最低。此外,健康对照组与MAP患者微生物群落的重合度小,而不同治疗方法的MAP患者之间的重合度相对较大。LEfSe分析显示,大承气汤降低了大肠埃希菌 - 志贺菌属和猪红斑丹毒丝菌的相对丰度,增加了三种有益菌,即乳酸杆菌属、罗伊氏菌属和布鲁氏菌属的相对丰度。在MAP患者肠道中,黏液乳杆菌和结膜乳杆菌显著富集。相关性分析显示,大肠埃希菌 - 志贺菌属与WBC、CRP、PCT、IL-6这四项炎症指标之间的正相关性具有统计学意义(r值分别为0.31、0.41、0.57、0.43,均P < 0.05)。其他细菌与炎症指标之间无显著相关性。治疗期间,MAP患者的血液、尿液、粪便、肾功能及ECG均无明显异常。

结论

大承气汤可通过调节肠道菌群组成减轻MAP患者的炎症反应,促进肠道微生态平衡及胃肠功能恢复。治疗期间未观察到明显不良反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验